News

Preclinical data of soquelitinib has demonstrated tumor responses in difficult to treat T-cell malignancies. The agent will now be evaluated in a phase 3 study in relapsed peripheral T cell lymphoma.

On the heels of positive results from GENESIS, a phase 3 study, the FDA has approved the first stem cell mobilization therapy for multiple myeloma.

Patients with heavily pretreated head and neck cancer achieved an overall response rate of 24% with enfortumab vedotin in the phase 2 EV-202 study.

Responses to BI 764532 in patient siwth DLL3-positive small cell lung cancer appear to be durable and are ongoing in the dose optimization portion of a phase 1 study.

In patients with metastatic non–small cell lung cancer given sacituzumab govitecan-hziy with pembrolizumab, positive response rates were observed.

Investigators reported the best objective response, progression-free survival, overall survival, and safety of a B7-H3–directed antibody-drug conjugate at the 2023 World Conference on Lung Cancer.

According to Baohui Han, MD, PhD, the confirmed objective response rate was 78.6% for treatment-naïve patients with non–small cell lung cancer with EGFR Exon20 insertion mutations treated with furmonertinib 240 mg daily in the FAVOUR trial.

Patritumab deruxtecan showed clinically meaningful and durable efficacy in the phase 2 HERTHENA-Lung01 trial of patients with advanced EGFR-mutated non–small cell lung cancer.

Phase 3 ETER701 study results reveal the benefit of adding benmelstobart to the standard combination of anlotinib and chemotherapy.

According to a presentation at SOHO 2023, overall survival was boosted among patients from the QuANTUM-First trial who went to transplant in first remission and were treated with quizartinib for their FLT3-ITD-positive acute myeloid leukemia.

Despite complete remission rates of up to 90%, late toxicities, such as secondary malignancies and cardiovascular events, are key concerns in patients treated for early-stage Hodgkin lymphoma.

With multiple JAK inhibitors now available to choose from, patient- and disease-specific factors are vital in determining the most appropriate therapy for patients with myelofibrosis.

Evolving research has now shown that immunotherapies can be combined with one another and used to specifically target the cancer cells.

Although chemotherapy has represented the standard therapeutic modality for indolent non-Hodgkin lymphoma, monoclonal antibodies, immunomodulatory agents, targeted agents, bispecific antibodies, and cellular therapies are now available.

The diffuse large B-cell lymphoma treatment landscape is evolving with Pola-R-CHP and CAR T-cell therapy moving into the frontline setting.

In an interview with Targeted Oncology, Amer Zeidan, MBBS, discussed the IMerge study and next steps for imetelstat for patients with lower-risk MDS.

Data points to the loss of predictive value of an interim PET2 scan for patients with Hodgkin lymphoma when treated with a regimen containing brentuximab vedotin.

Selecting and sequencing treatments in relapsed/refractory multiple myeloma involves balancing various factors due to limited historical data, as explained by Ajai Chari, MD, at the 2023 SOHO Annual Meeting.

The Independent Data Safety Monitoring Committee for the phase 2 ASCEND trial has given the okay to continue evaluation of LSTA1 for patients with pancreatic cancer.

Jonathan C. Trent, MD, PhD, discusses the methods, design, and results from the INTRIGUE study in advanced gastrointestinal stromal tumor.

Guidance from the FDA has provided a clear pathway and requested no additional efficacy or safety trials for the resubmission of the biologics license application for denileukin diftitox in cutaneous T-cell lymphoma.

At the SOHO 2023 Annual Meeting, Mohammad Bakri Hammami, MD, spoke about the need to address disparities related to race, sex, and age among patients with primary myelofibrosis to ensure that everyone receives high-quality treatment.

There was no difference in outcomes observed with intensive vs non-intensive consolidation chemotherapy regimens before allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia.

The median progression-free survival rates were 19.3 months with brigatinib and 19.2 months with alectinib in the phase 3 ALTA-3 study for patients with ALK-positive non–small cell lung cancer.

An analysis examined survival outcomes in several subgroups of patients with hematologic cancers compared with the overall population.

In an interview with Targeted Oncology, Marcia S. Brose, MD, PhD, FASCO discussed the impact of selpercatinib in thyroid cancer, and what to expect from the drug in the future.

Eytan M. Stein, MD, discusses trials evaluating Menin inhibitors for patients with acute leukemia and unmet needs that persist in the space.

INT230-6 is an investigational product candidate made up of cisplatin, vinblastine, and a penetration enhancer molecule being evaluated for patients with soft tissue sarcoma.

If approved, DB-1303 may provide a potential alternative to treatment with fam-trastuzumab deruxtecan-nxki for the treatment of patients with breast cancer.